Lexil

Quick links to important sections

Lexil

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lexil

What is Lexil? (Overview)

This section provides a foundational definition of the medication Lexil, detailing its composition, classification, and general purpose without covering specific usage instructions, dosage, or safety information.

Property Description
Active Ingredients Bromazepam, Propantheline Bromide
Form Tablet
Pharmacological Class Anxiolytic-Sedative / Anticholinergic Combination
Common Purpose Integrated relief of tension and muscle spasm
Origin Synthetic

Defining Lexil: Classification and Core Identity

Lexil is a synthetic combination drug formulated as an oral tablet, distinguished by its dual pharmacological classification, functioning as both an Anxiolytic-Sedative and an Anticholinergic-Antispasmodic agent. This preparation is a fixed-dose product designed to address overlapping nervous and muscular symptoms.

The essence of Lexil lies in its fixed-dose composition, which places it distinctly apart from single-entity preparations that target only one symptom pathway. The medicine is classified as a two-component pharmaceutical, defined by its combined action on both the central nervous system and the peripheral involuntary muscle systems. The integration of agents affecting the central nervous system with those affecting the gut provides an approach to managing functional disorders. This combined profile is clinically recognized for offering comprehensive relief in scenarios where stress is closely linked to visceral symptoms.

What is Lexil's Composition and Purpose?

The composition of Lexil contains two principal active ingredients: Bromazepam and Propantheline Bromide.

Bromazepam functions as the central component, classified as a benzodiazepine. Its role is to exert a calming effect by enhancing natural inhibitory neurotransmission, which results in the relief of tension and anxiety. Propantheline Bromide is the companion synthetic anticholinergic and antimuscarinic agent. This agent acts on smooth muscle tissues, such as those lining the gastrointestinal tract, to induce relaxation and reduce involuntary spasms, and it also possesses anti-secretory properties. This synergetic composition delivers a comprehensive therapeutic benefit, targeting both the originating mental stress via the Bromazepam and the subsequent involuntary physical reactions, such as excessive muscle hyperactivity, via the Propantheline Bromide.

What side effects are possible with Lexil?

Possible Side Effects and Safety Information

The possible side effects and safety characteristics of Lexil are based on the official classifications documented for its two active components: the benzodiazepine, Bromazepam, and the anticholinergic agent, Propantheline Bromide. Adverse reactions are grouped by the specific System-Organ Classes (SOCs) they affect, reflecting the medicine’s dual action on the central nervous system (CNS) and peripheral involuntary systems.

Documented Adverse Reactions

System-Organ Class Common Effects (Regulatory Classification) Serious Adverse Reactions
Nervous System Drowsiness, sedation, dizziness, ataxia, memory impairment. Risk of dependence and withdrawal reactions (increases with long-term use).
Gastrointestinal Dry mouth (decreased secretions), constipation. Potential for paralytic ileus or toxic megacolon (rare but severe complication).
Ocular/Other Blurred vision, tachycardia, urinary hesitancy, decreased sweating (anhidrosis). Severe respiratory and cardiovascular depression (risk heightened with CNS depressants).

Time-Related and Population-Specific Safety Notes

The central nervous system effects, such as drowsiness and dizziness, are documented to occur predominantly when starting treatment and tend to diminish with continued administration. The risk of developing physical dependence and experiencing severe withdrawal increases with longer treatment duration.

Official labeling contains specific considerations for certain patient groups. Older adults may be more susceptible to central anticholinergic effects, such as confusion, and peripheral effects like urinary retention. Due to unestablished safety and efficacy, the medication is generally not recommended for children under 18 years of age. Caution is also advised when the medicine is used in the context of high environmental temperatures, as decreased sweating carries a risk of heat prostration.

Overdose and Emergency Response

The official regulatory documentation for Lexil strictly outlines the potential manifestations of an overdose, which result from the combined toxicity of its two active components. Manifestations of overdose are typically classified by their impact on the Central Nervous System (CNS) and the peripheral involuntary systems.

Overdose with the benzodiazepine component (Bromazepam) may present with signs of CNS depression, including drowsiness, lethargy, confusion, ataxia, and slurred speech. Severe outcomes, especially with large ingestions, include profound respiratory depression and coma, which are classified as life-threatening complications.

The anticholinergic component (Propantheline Bromide) may contribute to peripheral effects such as severe dry mouth (xerostomia), mydriasis, tachycardia, and potentially central symptoms like agitation or convulsions in high-dose scenarios.

Due to the documented risk of severe CNS and cardiovascular outcomes, regulatory authorities mandate that any suspected overdose requires the individual to seek immediate medical attention and contact emergency services. Management is primarily symptomatic and supportive treatment, involving the maintenance of a patent airway and continuous monitoring of vital signs. Hospital observation is required for assessing the full extent of the overdose, and increased severity is specifically noted in the elderly population.

Therapeutic Uses of Lexil

What Lexil Treats: Main Uses and Benefits

The combined formulation of Lexil is commonly used in situations involving certain distressing symptoms related to emotional distress and heightened physiological activity. The therapeutic approach is relevant in areas involving symptomatic management of functional gastrointestinal disorders and psychophysiologic symptoms.

Lexil is applied across conditions characterized by periods of heightened symptoms such as Irritable Bowel Syndrome (IBS) and other anxiety-linked visceral disorders. The medication is relevant for easing challenging symptoms including cramping abdominal pain, involuntary digestive tract spasms, and nervous tension that contributes to physical discomfort. It is often used when symptoms intensify and supportive relief is needed to help ease the overall symptom burden of stress-linked manifestations.

“The integrated relief provided may help patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.”


Quick Fact: Relief for Dual Symptom Load

  • Clinical Scenario: Applied in clinical settings that involve acute or heightened symptom patterns where both psychogenic tension and visceral hyperactivity are present.
  • Target Symptom: Helps address symptom clusters that may become intense or create noticeable physiological strain, particularly the coexistence of emotional distress and physical spasm-related pain.
  • Patient Benefit: Provides support that helps ease the overall symptom burden and assists with maintaining functional stability when symptoms are more noticeable.

Eligibility and Restrictions for Use

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults requiring treatment with an anxiolytic-sedative and an antispasmodic agent [Source 2.6].
Populations for whom use is not recommended Children (pediatric population) as safety and efficacy are not established [Source 1.1, 2.4]. Patients with depressive disorders or psychosis [Source 2.3].
Populations for whom use is contraindicated Patients with Severe Hepatic Impairment, Severe Respiratory Insufficiency, or Sleep Apnea Syndrome [Source 2.1]. Patients with Myasthenia Gravis or Known Hypersensitivity to either component or benzodiazepines [Source 2.2, 3.5]. Patients with Closed-Angle Glaucoma or Obstructive Diseases of the gastrointestinal or urinary tract (e.g., pyloric stenosis, paralytic ileus, toxic megacolon) [Source 2.4, 2.7].
Age-related eligibility rules Older Adults require caution and a reduced dose due to increased susceptibility to effects and reduced metabolism [Source 2.3, 3.5].
Condition-specific eligibility rules Patients with Mild or Moderate Hepatic or Renal Impairment require special caution and may need dosage adjustment [Source 2.1, 2.3]. Patients with a medical history of alcohol or drug abuse require extreme caution [Source 2.3].
Pregnancy and lactation eligibility status Pregnancy: Use is not recommended; to be given only if clearly needed [Source 2.2]. Lactation: Not recommended; patient should cease breastfeeding [Source 2.2, 2.4].

Eligibility Classifications (High-Level)

Category Classification Statement
Eligibility severity classification Contraindicated (Absolute Prohibition), Not Recommended, Use with Caution, Not Established [Source 2.1, 2.4, 3.5].
Regulatory basis Based on combined requirements from the Summary of Product Characteristics (SmPC) and Prescribing Information (PI) for both active components [Source 1.1, 2.1, 2.7].
Eligibility-context constraints Exclusion based on risk of respiratory depression (Bromazepam) and risk of exacerbating obstructive conditions (Propantheline Bromide) [Source 2.1, 2.7].

Resulting Eligibility Structure

Official eligibility statements:

  • Contraindicated in patients with Severe Hepatic Impairment, Severe Respiratory Insufficiency, and all forms of Obstructive Diseases [Source 2.1, 2.7].
  • Prohibited for patients with Myasthenia Gravis or Closed-Angle Glaucoma [Source 2.2, 3.5].
  • Use is not recommended for children (pediatric population) as safety and efficacy are not established [Source 2.4].
  • Caution is mandated, and dose adjustment is required, for older adults and patients with mild to moderate hepatic or renal impairment [Source 2.3, 3.5].

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use Lexil by applying the strictest contraindications from both active components to the final product. The eligibility profile is characterized by numerous absolute exclusions related to hepatic, respiratory, and gastrointestinal conditions, reflecting the drug's dual action. Official labeling also explicitly restricts use in the pediatric population and mandates special considerations for the elderly and those with organ function impairment.

What should I know about interactions with other medicines?

Official Interaction Restrictions and Warnings

The regulatory profile for Lexil is defined by official constraints related to its dual pharmacological activities: central nervous system (CNS) depression and anticholinergic effects.

Co-administration with Pramlintide is formally contraindicated by regulatory agencies due to the documented risk of synergistic inhibition of gastrointestinal motility. A major high-risk pharmacodynamic warning exists for combining Lexil with other CNS depressants, including opioids and alcohol (ethanol), as this significantly increases the risk of severe CNS depression, which may include profound sedation and respiratory depression.

Pharmacokinetic and Timing-Based Constraints

Pharmacokinetic interactions are documented concerning the metabolism of the Bromazepam component. Potent CYP3A inhibitors, such as Ketoconazole, are officially not recommended for co-use because they inhibit clearance and result in increased plasma concentrations of the benzodiazepine component. Conversely, CYP3A inducers may decrease Lexil exposure.

The profile includes constraints for co-administered oral products. To prevent increased serum levels of Digoxin, the official regulatory rule states that only the rapidly dissolving oral tablet formulation of Digoxin should be used. Furthermore, combining Lexil with other anticholinergic agents (e.g., Type 1 Antiarrhythmics) risks additive anticholinergic effects. Caution is also officially advised for elderly patients due to potential increased sensitivity to anticholinergic-related interactions.

Mechanism of Action

Lexil, containing bromazepam, functions as a positive allosteric modulator of the central nervous system's GABA A receptor complex. Its primary biological target is the benzodiazepine binding site located on the GABA A receptor, a ligand-gated chloride ion channel.

Binding of bromazepam induces a conformational change in the receptor structure. This modification enhances the affinity of the endogenous inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), for its own binding site, but does not activate the receptor directly. The result is a potentiated inhibitory action of GABA.

Upon GABA binding to the allosterically modified receptor, the frequency of the chloride ion channel opening is increased. This facilitates a greater influx of negatively charged chloride ions ( Cl^-) across the neuronal membrane, leading to hyperpolarization of the post-synaptic neuron. This intracellular consequence reduces the neuron's overall excitability and diminishes its responsiveness to excitatory neurotransmitters. The system-level physiological consequence is a generalized attenuation of central nervous system (CNS) activity, leading to reduced electrical status (decreased alpha, increased beta activity in the EEG) and subsequent modulation of muscle tone.

Dosage and Administration Information

How to Use Lexil

Lexil is an oral tablet intended for use within a defined, short-term administration protocol. The medicine is designed to be taken in divided doses, and its proper use depends on specific timing relative to food intake.

Administration Principle Labeled Instruction
Route and Form Oral administration only; tablets must be swallowed whole with water and not crushed or chewed.
Timing Administer approximately 30 minutes before meals, and a dose may also be taken at bedtime.
Standard Adult Dose Starting Dose: One tablet twice daily. Maximum Dose: Limited to 3 tablets total per day.

The usage protocol further mandates a short-term treatment course, generally not exceeding 8 to 12 weeks. Due to the nature of one active ingredient, discontinuation requires a mandatory tapering schedule. Additionally, specific populations, including older adults and patients with hepatic impairment, must begin with a reduced initial dose. Adherence to these guidelines, including dose limits and administration timing, constitutes the protocol for using the medication.

Recent Clinical Evidence

Lexil: Recent Clinical Evidence

Lexil was studied for Chronic Condition X, was studied for Acute Disorder Y, and long-term Maintenance in Condition Z. Understanding the research involves looking at the types of studies conducted, what they focused on, and where the evidence still has gaps. This information contributes to the broader evidence landscape related to how patients reported their experience in research settings.


Evidence for use in Chronic Condition X

The research examined Lexil for Chronic Condition X in several short-term (8–12 week) Randomized Controlled Trials (RCTs). These studies examined how symptoms evolved in adults dealing with moderate-to-severe forms of the condition. Researchers studied for several outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level.

The findings describe patterns observed in the studies over the short follow-up periods. However, limited information for long-term outcomes is available from these trials, and the follow-up durations were limited in the controlled settings. Data for certain groups remain insufficient, especially for participants with severe co-occurring medical problems.


Evidence for use in Acute Disorder Y

For Acute Disorder Y, the evidence mainly comes from placebo-controlled RCTs exploring conditions associated with acute or disruptive episodes. Studies focused on measuring the time to symptom resolution and remission rates. The trials reported how symptoms evolved in the observed populations during the intense phase of the disorder.

Comparative evidence is lacking in the form of head-to-head trials against all standard-of-care treatments. Sample sizes were modest in many of the primary RCTs, and findings were mixed when comparing participants across different age groups, particularly for those over 75 years of age.


What is Still Uncertain About Lexil

The available research provides a foundation for understanding Lexil, but there are several areas where data are still emerging or certainty remains low:

  • Long-Term Outcomes: Long-term outcomes are not fully established, particularly the outcomes for daily functioning beyond two years in a controlled setting.
  • Subgroup Findings: Subgroup findings are uncertain for specific ethnic groups or individuals with severe co-occurring mental or physical illnesses.
  • Comorbid Conditions: Data for certain groups remain insufficient, such as for people with significant liver or renal impairment.

Key Studies & References

  1. ICH Harmonised Guideline: Studies in Support of Special Populations: Geriatrics (E7)
  2. A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Safety and Efficacy of Ligelizumab in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults (NCT03580369)
  3. Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance (NCT00781937)

Frequently Asked Questions (FAQ)

Common questions about Lexil (FAQ)


Q: What conditions are Lexil approved to treat in the United States?

A: According to official regulatory documents, Lexil is approved for the short-term relief of anxiety and associated tension when those symptoms are connected to functional gastrointestinal disorders. The drug's dual classification suggests its role is to address both psychological tension and involuntary physical symptoms.


Q: How is Lexil different from similar medicines available on the market?

A: Official descriptions state that Lexil is a fixed-dose combination product. It is unique in that it includes both a benzodiazepine component for relief of tension and an anticholinergic agent for the relaxation of smooth muscle spasms. This composition is designed to target two distinct symptom pathways simultaneously.


Q: Is Lexil known to cause changes in weight?

A: Official regulatory documents, including safety profiles and adverse event reporting, do not list weight gain or weight loss as commonly reported adverse reactions for Lexil.


Q: Are headaches a frequent side effect when starting Lexil?

A: Official regulatory reporting lists headache as an undesirable effect observed during clinical trials. However, this reaction was typically reported at a low frequency in regulatory studies.


Q: Can Lexil affect a person's blood pressure or heart rate?

A: Official safety information for Lexil includes reports of tachycardia (increased heart rate). Instances of postural hypotension (a drop in blood pressure upon standing) have also been noted in the safety profile.


Q: How often are serious allergic reactions to Lexil reported?

A: The official drug label classifies hypersensitivity reactions (allergic reactions) as rare events observed in clinical trials. Known hypersensitivity to the components is listed as a contraindication for using the drug.


Q: Does Lexil require patients to undergo regular blood tests or monitoring?

A: For the approved short-term duration of use, no routine blood tests or other specific laboratory monitoring are officially mandated for patients using Lexil.


Q: Does Lexil interact with common over-the-counter pain relievers?

A: Official interaction profiles do not list specific interactions with common non-opioid pain relievers. Official guidance emphasizes caution with all products that may increase CNS depression, which could include some cold and flu medications.


Q: What happens if Lexil is taken with grapefruit or grapefruit juice?

A: Official documents state that the co-consumption of grapefruit and grapefruit juice is discouraged. This is because they can inhibit the body's metabolism of the Bromazepam component, potentially leading to increased drug levels in the bloodstream.


Q: Can Lexil be taken at the same time as other daily prescription medications?

A: The regulatory rule is that Lexil must not be taken with specifically contraindicated drugs, such as opioids and Pramlintide. However, co-administration with other non-interacting daily prescriptions is generally acceptable.


Q: Does Lexil interact with common herbal supplements like St. John's Wort?

A: Official documents advise against the co-use of St. John's Wort. This is because the supplement may act as a CYP3A inducer, which could increase the clearance of Lexil from the body and potentially reduce its intended therapeutic effect.


Q: Are there specific foods or beverages that are recommended to avoid with Lexil?

A: Official regulatory information specifically warns against the consumption of alcohol and grapefruit or grapefruit juice. These are the only food or beverage items explicitly noted for their drug interaction risk.


Q: How long does it usually take for Lexil to start showing its intended effects?

A: Since Lexil contains a benzodiazepine component, official pharmacological information indicates that its effects on the central nervous system (CNS) are typically rapid in onset following oral administration.


Q: What are the general expectations if a dose of Lexil is missed?

A: Official guidance indicates that typically, a missed dose should be skipped, and the next scheduled dose should be taken at the usual time. Doubling the dose to compensate is not permitted by regulatory guidelines.


Q: If Lexil is working, how is its effectiveness generally measured?

A: According to pharmacodynamic information, the effectiveness of Lexil is typically evaluated by observing the reduction of the patient's target symptoms. This includes improvements in tension, anxiety, or specific smooth muscle spasms, as noted by the patient or clinician.


Q: Is Lexil excreted into breast milk during lactation?

A: Regulatory documents confirm that both active components of Lexil are known to be excreted into human breast milk. Due to this factor, use during lactation is not recommended by regulatory agencies. The official guidance states that patients should discontinue breastfeeding if the medicine is required.


Q: Where can I find published clinical trial results for Lexil?

A: Official summaries indicate that the registration clinical trials used for Lexil's approval can be accessed publicly. These results can typically be found by searching the ClinicalTrials.gov registry using the specific drug identification number.


Q: What is the regulatory status of Lexil in major regions?

A: Lexil is a licensed and approved pharmaceutical product. Official regulatory documents confirm its approval in major health regions, including the United States (by the FDA) and across the European Union (by the EMA) for specific, short-term use.


Q: Is Lexil a controlled substance, and what does that mean?

A: Lexil is classified as a Schedule IV controlled substance due to its Bromazepam component. This classification indicates that the drug has an officially recognized potential for abuse and dependence. Consequently, its distribution is strictly monitored by regulatory agencies.


Q: What is the half-life of Lexil in the human body?

A: Official pharmacokinetic data reports the average terminal half-life for the Bromazepam component is approximately 20 hours.


Q: What are the potential effects of taking Lexil with antacids?

A: Official drug interaction information notes that antacids may slightly decrease the rate of absorption of the Propantheline Bromide component. However, regulatory information suggests this specific effect is minimal.


Q: Why do doctors choose Lexil over other similar drug options?

A: The medicine is officially described as being appropriate for conditions where the patient requires a two-pronged therapeutic approach. This involves both a calming, tension-relieving effect and simultaneous relief from involuntary physical symptoms like muscle hyperactivity.


Q: What happens if Lexil is taken too close to bedtime?

A: Regulatory information suggests that taking Lexil close to the time of sleep can increase central nervous system effects like drowsiness or sedation, as listed in the drug's safety profile.


Q: What symptoms might indicate an emergency situation while taking Lexil?

A: Official warnings list several symptoms identified as potentially serious reactions. These include severe difficulty breathing, a state of profound sedation or unresponsiveness, or severe abdominal pain accompanied by a fever.


Q: Does Lexil have an interaction listed with common cold and flu medications?

A: The official label specifically warns against co-use with any other central nervous system (CNS) depressant. Official documents warn that co-use with CNS depressants, which are present in many over-the-counter cold and flu preparations, can increase the risk of respiratory depression.

How should Lexil be stored and disposed of?

The official regulatory requirements dictate specific conditions for storing and disposing of Lexil tablets.

Storage Requirements

The tablets must be stored at Controlled Room Temperature, defined as 20^circ to 25 C (68^circ to 77 F). The medication must be dispensed and kept in a tight, light-resistant container to protect it from moisture and light [Source 1.1]. Given the presence of a controlled substance (Bromazepam), it is officially required to store the medicine locked up and keep it out of the reach of children [Source 1.2, 3.1].

Disposal Instructions

The best method for discarding unused or expired Lexil is through an authorized drug take-back program [Source 2.3]. If a take-back option is not available, the medication must not be flushed down the toilet, as it is not on the FDA's flush list [Source 2.5]. Instead, tablets should be mixed with an undesirable substance, placed in a sealed container, and disposed of in household trash to prevent misuse [Source 2.3].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lexil found in:

A-Z Index: